Abstract
Autism spectrum disorders (ASD) are a cluster of developmental disorders, whose core symptoms can be attributed to abnormal development of the large-scale neural networks required for social communication. The impaired delivery of afferent signals has been proposed to be associated with impaired social interaction in ASD. Arachidonic acid (ARA) and docosahexaenoic acid (DHA) play key roles in the maturation of brain network. In particular, ARA promotes signal transduction related to neural function. It is therefore possible that supplementation with larger ARA doses added to DHA may mitigate the impaired social interaction observed in ASD. There have been no double-blind randomized placebo-controlled studies of the effect of large doses of ARA, added to DHA, on the impaired social interactions observed in ASD. This article presents the results of a 16-week double-blind randomized placebo-controlled trial in which high-dose ARA was added to DHA supplementation in individuals with ASD (n=13). The primary outcomes were measured using the Social Responsiveness Scale (SRS) and the secondary outcome measure was Autism Diagnostic Interview-revised (ADI-R) social and communication domains. Supplementation of larger doses of ARA added to DHA significantly improved SRS-measured communication and ADI-measured social communication. At the end of trial, the increase in plasma ARA levels from the baseline observed in the ARA treatment group was significantly higher compared to placebo group.
Keywords: Autism spectrum disorders, impaired social interaction, arachidonic acid, dietary supplementation, clinical trial, signal transduction
Current Psychopharmacology
Title:Effects of Adding Large Doses of Arachidonic Acid to Docosahexaenoic Acid on Social Impairment in Individuals with Autism Spectrum Disorders
Volume: 2
Author(s): K. Yui, K. Koshiba and S. Nakamura
Affiliation:
Keywords: Autism spectrum disorders, impaired social interaction, arachidonic acid, dietary supplementation, clinical trial, signal transduction
Abstract: Autism spectrum disorders (ASD) are a cluster of developmental disorders, whose core symptoms can be attributed to abnormal development of the large-scale neural networks required for social communication. The impaired delivery of afferent signals has been proposed to be associated with impaired social interaction in ASD. Arachidonic acid (ARA) and docosahexaenoic acid (DHA) play key roles in the maturation of brain network. In particular, ARA promotes signal transduction related to neural function. It is therefore possible that supplementation with larger ARA doses added to DHA may mitigate the impaired social interaction observed in ASD. There have been no double-blind randomized placebo-controlled studies of the effect of large doses of ARA, added to DHA, on the impaired social interactions observed in ASD. This article presents the results of a 16-week double-blind randomized placebo-controlled trial in which high-dose ARA was added to DHA supplementation in individuals with ASD (n=13). The primary outcomes were measured using the Social Responsiveness Scale (SRS) and the secondary outcome measure was Autism Diagnostic Interview-revised (ADI-R) social and communication domains. Supplementation of larger doses of ARA added to DHA significantly improved SRS-measured communication and ADI-measured social communication. At the end of trial, the increase in plasma ARA levels from the baseline observed in the ARA treatment group was significantly higher compared to placebo group.
Export Options
About this article
Cite this article as:
Yui K., Koshiba K. and Nakamura S., Effects of Adding Large Doses of Arachidonic Acid to Docosahexaenoic Acid on Social Impairment in Individuals with Autism Spectrum Disorders, Current Psychopharmacology 2013; 2 (1) . https://dx.doi.org/10.2174/2211556011302010084
DOI https://dx.doi.org/10.2174/2211556011302010084 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Information of ADME-Associated Proteins and Potential Application for Pharmacogenetic Prediction of Drug Responses
Current Pharmacogenomics Phosphodiesterases as Therapeutic Targets for Huntington’s Disease
Current Pharmaceutical Design HTR2A Gene Variants and Psychiatric Disorders: A Review of Current Literature and Selection of SNPs for Future Studies
Current Medicinal Chemistry Group I Metabotropic Glutamate Receptor Signalling and its Implication in Neurological Disease
CNS & Neurological Disorders - Drug Targets Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) 3-Methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol: the Importance of Functional Groups for Antiparkinsonian Activity
Medicinal Chemistry The Use of Antiparkinsonian Agents in the Management of Drug-Induced Extrapyramidal Symptoms
Current Pharmaceutical Design Pharmacogenetics of Cytochrome P450 (CYP) 1A2 and Variability in Psychotropic Drug Response
Current Psychiatry Reviews Pediatric Catatonia: Updating An Old Syndrome in Young People
Current Psychiatry Reviews Lower K<sub>V</sub>7.5 Potassium Channel Subunit Expression in an Animal Model of Paroxysmal Dystonia
CNS & Neurological Disorders - Drug Targets Bis(thiosemicarbazone) Metal Complexes as Therapeutics for Neurodegenerative Diseases
Current Topics in Medicinal Chemistry The Concept of “Neuroprotection” in Neurological Diseases
Current Neuropharmacology Transgenic Mouse Models of Tauopathy in Drug Discovery
CNS & Neurological Disorders - Drug Targets Targeting Striatal Metabotropic Glutamate Receptor Type 5 in Parkinson’s Disease: Bridging Molecular Studies and Clinical Trials
CNS & Neurological Disorders - Drug Targets Patterns of Self-Medication with Medicinal Plants and Related Adverse Events - A South American Survey
Current Drug Safety A2A Receptor Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry Monoamine Oxidase Inhibitors Extracted from Tobacco Smoke as Neuroprotective Factors for Potential Treatment of Parkinson`s Disease
CNS & Neurological Disorders - Drug Targets Current Research on Opioid Receptor Function
Current Drug Targets Basic Pharmacology of NMDA Receptors
Current Pharmaceutical Design Potential Benefits and Limits of Psychopharmacological Therapies in Pervasive Developmental Disorders
Current Clinical Pharmacology